Servier (Private)
Quick facts
| Ticker | Private (Private) |
|---|
Marketed products
- Tibsovo · Oncology
Ivosidenib inhibits mutant IDH1, reducing 2-HG levels and promoting myeloid differentiation in AML. - Voranigo · Oncology
Voranigo works by blocking the activity of an enzyme called isocitrate dehydrogenase 1.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: